AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28284475 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute bronchiolitis
Number of subjects: 531
Study 28284475 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 531
Study 28284475 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys at 2 years of age
Number of subjects: 531
Study 28284475 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls at 2 years of age
Number of subjects: 531
Study 28284475 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants at the time of acute bronchiolitis
Number of subjects: 531
Study 28284475 — intervention group
Group type: COMPARATOR
Intervention: Reference group at 2 years of age
Number of subjects: 531
Study 28284475 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls at 2 years of age vs Boys
Number of subjects: 531
Study 28284536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dactylis glomerate pollen challenge (4-hour duration, two challenges with 21 days interval)
Number of subjects: 34
Study 28284536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dactylis glomerate pollen challenge (4-hour duration, second challenge)
Number of subjects: 34
Study 28284536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dactylis glomerate pollen challenge (4-hour duration, repetitive challenge)
Number of subjects: 34
Study 28284536 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nasal symptom score
Number of subjects: 34
Study 28284536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal nitric oxide levels
Number of subjects: 34
Study 28284916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell (MSC) infusion (1.5-3×10^6 cells)
Number of subjects: 10
Study 28284916 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard immunosuppression without MSC infusion)
Number of subjects: 10
Study 28284978 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU/kg of recombinant human C1 esterase inhibitor (rhC1INH)
Number of subjects: 127
Study 28285070 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-level FRAX score calculation with bone mineral density
Number of subjects: 6096
Study 28285070 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening-level FRAX score
Number of subjects: 6096
Study 28285236 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA+DEX
Number of subjects: 1460
Study 28285236 — intervention group
Group type: COMPARATOR
Intervention: oral PALO+DEX
Number of subjects: 1460
Study 28285240 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy associated with SKY (Treatment)
Number of subjects: 46
Study 28285240 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 46
Study 28285311 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensor monitoring of spontaneous daily physical activity (PAMSys™, BioSensics LLC)
Number of subjects: 120
Study 28286093 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided needle-based confocal laser endomicroscopy (nCLE) for diagnosing mucinous PCLs
Number of subjects: 29
Study 28286093 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided needle-based confocal laser endomicroscopy (nCLE) for diagnosing serous cystadenomas (SCAs)
Number of subjects: 29
Study 28286093 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement (IOA) for nCLE image patterns
Number of subjects: 29
Study 28286093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reliability (IOR) for nCLE image patterns
Number of subjects: 29
Study 28286093 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement (IOA) for recognizing SCA image pattern
Number of subjects: 29
Study 28286093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reliability (IOR) for recognizing SCA image pattern
Number of subjects: 29
Study 28286192 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 70
Study 28286536 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ucOC
Number of subjects: 318
Study 28286536 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum tOC
Number of subjects: 318
Study 28286803 — intervention group
Group type: EXPERIMENTAL
Intervention: D2C7-(scdsFv)-PE38KDEL (D2C7-IT) immunotoxin therapy
Number of subjects: 0
Study 28286967 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 agents
Number of subjects: 800
Study 28286967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 28287157 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heating (LH)
Number of subjects: 17
Study 28287157 — intervention group
Group type: EXPERIMENTAL
Intervention: Current induced vasodilation (CIV)
Number of subjects: 17
Study 28287157 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-occlusive hyperemia (PORH)
Number of subjects: 17
Study 28287157 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine (ACh)
Number of subjects: 17
Study 28287157 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 17
Study 28288572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with modified FOLFIRI (mFOLFIRI)
Number of subjects: 61
Study 28288655 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated notification system for deteriorating ward patients (after intervention)
Number of subjects: 4402
Study 28288655 — intervention group
Group type: COMPARATOR
Intervention: Control group (before intervention)
Number of subjects: 4402
Study 28288678 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Coordination Intervention (CCI) consisting of a tablet-based mobile platform, interagency communication protocol, and training protocol.
Number of subjects: 60
Study 28288678 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Coordination Intervention (CCI)
Number of subjects: 60
Study 28288682 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA continuation (n=61)
Number of subjects: 135
Study 28288682 — intervention group
Group type: COMPARATOR
Intervention: ADA discontinuation (n=74)
Number of subjects: 135
Study 28288682 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial intensive therapy (ADA + MTX)
Number of subjects: 135
Study 28288682 — intervention group
Group type: COMPARATOR
Intervention: ADA discontinuation
Number of subjects: 135
Study 28288682 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA continuation
Number of subjects: 135
Study 28288747 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS only
Number of subjects: 2018
Study 28288747 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS plus 75 KES
Number of subjects: 2018
Study 28288747 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS plus 200 KES
Number of subjects: 2018
Study 28288747 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2018
Study 28288747 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS plus 200 KES vs Control
Number of subjects: 2018
Study 28288963 — intervention group
Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HPR) defined as P2Y12 reaction units >208
Number of subjects: 8582
Study 28288963 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral arterial disease (PAD)
Number of subjects: 8582
Study 28288963 — intervention group
Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HPR)
Number of subjects: 8582
Study 28288963 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with both PAD and HPR
Number of subjects: 8582
Study 28288963 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 8582
Study 28289008 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28289025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose primaquine
Number of subjects: 0
Study 28289046 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA) for fertility preservation
Number of subjects: 0
Study 28289046 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative evaluation of PtDA usage
Number of subjects: 0
Study 28289046 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative feedback
Number of subjects: 0
Study 28289215 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement kit consisting of monoamine precursor amino acids and dietary antioxidants (including tryptophan and tyrosine)
Number of subjects: 41
Study 28289215 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 41
Study 28289402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide SC injection
Number of subjects: 6
Study 28290120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clindamycin dosing of 9 mg/kg/dose for children ≤5 months, 12 mg/kg/dose for children >5 months-6 years, and 10 mg/kg/dose for children 6-18 years, administered every 8 hours.
Number of subjects: 0
Study 28290120 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal dosing proposed by the pediatric PBPK model.
Number of subjects: 0
Study 28290744 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted MVPA-focused intervention for students with elevated impulsiveness and cognitive dissonance
Number of subjects: 333
Study 28291376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioversion of atrial fibrillation to sinus rhythm
Number of subjects: 23
Study 28291584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 2 weeks for up to 2 years)
Number of subjects: 25
Study 28291640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a (initial dose 450 μg subcutaneously once per week, reduced to 90 mg per week)
Number of subjects: 83
Study 28291640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Number of subjects: 83
Study 28291870 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab, 420 mg plus standard of care (SOC)
Number of subjects: 1324
Study 28291870 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 1324
Study 28291870 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab, 420 mg plus SOC
Number of subjects: 1324
Study 28291870 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab treatment
Number of subjects: 1324
Study 28292280 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia patients
Number of subjects: 1707
Study 28292280 — intervention group
Group type: COMPARATOR
Intervention: Non-diseased persons
Number of subjects: 1707
Study 28292290 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct reduction (DR) technique through posterolateral approach
Number of subjects: 116
Study 28292290 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct reduction (DR) technique
Number of subjects: 116
Study 28292290 — intervention group
Group type: COMPARATOR
Intervention: Indirect reduction (IR) technique using ligamentotaxis
Number of subjects: 116
Study 28292858 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-sex percentiles of segment involvement score (SIS)
Number of subjects: 21132
Study 28292858 — intervention group
Group type: COMPARATOR
Intervention: SIS% groups (≤50th, 51-75th, >75th)
Number of subjects: 21132
Study 28292941 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1129980 (C4.4A-ADC), an antibody-drug conjugate targeting C4.4A
Number of subjects: 0
Study 28292947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous plerixafor at a dose of 0.32 mg/kg
Number of subjects: 0
Study 28292947 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous plerixafor (not specified in detail)
Number of subjects: 0
Study 28293022 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adapted consolidation with bortezomib after ASCT
Number of subjects: 0
Study 28293270 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa (1.85 g leaf powder/day)
Number of subjects: 11
Study 28293280 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg of ramosetron
Number of subjects: 115
Study 28293280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 28293424 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAD (Smoothly Clipped Absolute Deviation)
Number of subjects: 0
Study 28293424 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive LASSO (Least Absolute Shrinkage and Selection Operator)
Number of subjects: 0
Study 28293424 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP (Minimax Concave Penalty)
Number of subjects: 0
Study 28293424 — intervention group
Group type: COMPARATOR
Intervention: Traditional stepwise regression method
Number of subjects: 0
Study 28293424 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation markers (Myeloperoxidase (MPO) at week 12 and soluble CD14 at week 18)
Number of subjects: 0
Study 28293424 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother weight and height-for-age z-score (HAZ) at week 18
Number of subjects: 0
Study 28293431 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages plus phone call reminders
Number of subjects: 40
Study 28293431 — intervention group
Group type: COMPARATOR
Intervention: Phone call reminders only (usual care)
Number of subjects: 40
Study 28295849 — intervention group
Group type: EXPERIMENTAL
Intervention: simeprevir (SMV), daclatasvir (DCV), and ribavirin (RBV) for 24 weeks
Number of subjects: 35
Study 28296283 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial CD34 treatment, details on dosage and duration not provided
Number of subjects: 0
Study 28296283 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28296993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulitis
Number of subjects: 54
Study 28297015 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued thienopyridine therapy
Number of subjects: 11648
Study 28297015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11648
Study 28298048 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurements of physical strain within carotid atherosclerotic plaques
Number of subjects: 0
Study 28298048 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of microemboli
Number of subjects: 0
Study 28298048 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter hyperintensity
Number of subjects: 0
Study 28298401 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after radiation therapy (SMART)
Number of subjects: 65
Study 28298402 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 13
Study 28298564 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate treatment
Number of subjects: 0
Study 28298564 — intervention group
Group type: COMPARATOR
Intervention: Nilotinib treatment (control group for signature validation)
Number of subjects: 0
Study 28299283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg daily until disease progression or unacceptable toxicity
Number of subjects: 17
Study 28300867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg bid
Number of subjects: 180
Study 28300867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid
Number of subjects: 180
Study 28300867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 28301073 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center hemodialysis (6 d/wk)
Number of subjects: 195
Study 28301073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal home hemodialysis (6 nights/wk)
Number of subjects: 195
Study 28301073 — intervention group
Group type: COMPARATOR
Intervention: Conventional thrice-weekly hemodialysis
Number of subjects: 195
Study 28302081 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Questionnaire for Physical Therapists (MSQPT)
Number of subjects: 0
Study 28302081 — intervention group
Group type: COMPARATOR
Intervention: HAQUAMS (control)
Number of subjects: 0
Study 28302090 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy
Number of subjects: 455
Study 28302090 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-alone regimens
Number of subjects: 455
Study 28302090 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rates
Number of subjects: 455
Study 28302090 — intervention group
Group type: EXPERIMENTAL
Intervention: CLL-related deaths in LOT1
Number of subjects: 455
Study 28302090 — intervention group
Group type: EXPERIMENTAL
Intervention: CLL-related deaths in LOT≥2
Number of subjects: 455
Study 28302090 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection-related deaths in LOT1
Number of subjects: 455
Study 28302090 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection-related deaths in LOT≥2
Number of subjects: 455
Study 28302090 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score for E-CLL patients
Number of subjects: 455
Study 28302137 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) followed by two cycles of R (R-CHOP-14)
Number of subjects: 76
Study 28303154 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs); specific dosage and duration not mentioned.
Number of subjects: 0
Study 28303154 — intervention group
Group type: COMPARATOR
Intervention: Not specified; control group not mentioned.
Number of subjects: 0
Study 28303154 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified; ongoing studies include MSCs therapy in emphysema and several studies of ADSCs in COPD.
Number of subjects: 0
Study 28304217 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide (oral immunomodulator, once-daily)
Number of subjects: 0
Study 28304217 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 0
Study 28306749 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (smokers, n = 277)
Number of subjects: 931
Study 28306749 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking (non-smokers, n = 654)
Number of subjects: 931
Study 28314691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone mouthwash (10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL oral solution, swish for 2 min and spit, four times daily for 8 weeks)
Number of subjects: 92
Study 28314691 — intervention group
Group type: COMPARATOR
Intervention: Historical controls from the BOLERO-2 trial (everolimus and exemestane treatment without dexamethasone mouthwash)
Number of subjects: 92
Study 28314691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone mouthwash
Number of subjects: 92
Study 28314699 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib 150 mg twice a day, Lenalidomide 15 mg on days 1-21 in a 28-day cycle, Rituximab 375 mg/m2 (initially included)
Number of subjects: 11
Study 28314699 — intervention group
Group type: COMPARATOR
Intervention: Idelalisib 150 mg twice a day, Lenalidomide 15 mg on days 1-21 in a 28-day cycle
Number of subjects: 11
Study 28314711 — intervention group
Group type: EXPERIMENTAL
Intervention: HERDOO2 rule
Number of subjects: 0
Study 28314788 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib added to Bendamustine and Rituximab
Number of subjects: 0
Study 28314788 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine and Rituximab alone
Number of subjects: 0
Study 28314833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus
Number of subjects: 277
Study 28314833 — intervention group
Group type: COMPARATOR
Intervention: No Diabetes Mellitus
Number of subjects: 277
Study 28314833 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure
Number of subjects: 277
Study 28314833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intima-Media Thickness
Number of subjects: 277
Study 28314833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatation of Retinal Veins in Response to Flicker Light
Number of subjects: 277
Study 28314833 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine Levels
Number of subjects: 277
Study 28314833 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous Dilatation in Response to Flicker Light
Number of subjects: 277
Study 28314862 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI cases
Number of subjects: 557
Study 28314862 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 557
Study 28315940 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including low tidal volume (≤7 ml/kg), moderate PEEP (6-8 cm H2O), and early extubation.
Number of subjects: 744
Study 28315940 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with recommendations (n=60, 8% of patients).
Number of subjects: 744
Study 28317031 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 28317031 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28318045 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding epithelial hyperplasia as a criterion
Number of subjects: 231
Study 28318045 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-based GERD diagnosis without epigastric pain
Number of subjects: 231
Study 28318045 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology
Number of subjects: 231
Study 28318100 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-treated blood at 45 °C for 15 hours
Number of subjects: 6
Study 28318100 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-treated material
Number of subjects: 6
Study 28318636 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Laser Treatment
Number of subjects: 0
Study 28318636 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no treatment)
Number of subjects: 0
Study 28319446 — intervention group
Group type: EXPERIMENTAL
Intervention: Transduced UCB CD34+ cells
Number of subjects: 20
Study 28319446 — intervention group
Group type: COMPARATOR
Intervention: Mock-transduced UCB CD34+ cells
Number of subjects: 20
Study 28319597 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center nocturnal hemodialysis
Number of subjects: 57
Study 28319597 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 57
Study 28320214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients
Number of subjects: 32
Study 28320242 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, goal-directed therapy (EGDT)
Number of subjects: 3723
Study 28320242 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3723